-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, CDE issued the Technical Guidelines for the Evaluation of Similarity of Biologicalsimilars and the Extrapolation of Indications
.
In this regard, industry insiders commented: The "consistency evaluation" of biosimilar drugs is coming and will also be included in centralized procurement in the future
.
Previously, biopharmaceuticals were once known as the "forbidden zone for volume procurement", which could avoid the price impact of centralized procurement
.
In addition, the research and development cost of biosimilar drugs is lower than that of original innovative drugs, and many domestic and foreign companies are more enthusiastic about biosimilar drugs
.
Now that the "forbidden zone" is broken, this will naturally bring down the enthusiasm of the company
.
As far as adalimumab is concerned, the original price of the original research drug Xiu Meile is 7586 yuan/piece (40ml), the medical insurance payment price is 1,290 yuan/piece, and Biotech’s Gelli is priced at 1,160 yuan/piece, and Hisun Pharmaceuticals The price of An Jianning and Cinda Bio's Su Lixin are both 1150 yuan/piece
.
The Handa of Fuhong Hanli is far 899 yuan/piece
.
If we refer to the 75% average drop in the centralized procurement of chemical drugs, the price of biosimilar drugs after the centralized procurement is expected to drop to less than 1,000 yuan
.
This is undoubtedly a head-on blow to companies including Pfizer that have not yet entered the market
.